All-cause mortality and cardiovascular safety of basal insulin treatment in patients with type 2 diabetes mellitus: A systematic review with meta-analysis and trial sequential analysis

Association of Insulin Dose, Cardiometabolic Risk Factors, and Cardiovascular Disease in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study

(2019) Barbara H. Braffett et al.   DIABETES CARE

Patient-Reported Outcomes in T2D Patients Inadequately Controlled by Metformin Are More Favorable for Dapagliflozin plus Saxagliptin vs. Insulin Glargine

(2018) MARCIA A. TESTA et al.   DIABETES

Efficacy and Safety of Once-weekly Dulaglutide Versus Insulin Glargine in Mainly Asian Patients with Type 2 Diabetes Mellitus on Metformin and/or a Sulfonylurea: a 52-week Open-label, Randomized Phase 3 Trial

(2018) Weiqing Wang et al.   DIABETES OBESITY & METABOLISM

Effects of exenatide versus insulin glargine on body composition in overweight and obese T2DM patients: a randomized controlled trial

(2018) Ting-Ting Yin et al.   Nutrition & Metabolism

Association of insulin dosage with mortality or major adverse cardiovascular events: a retrospective cohort study

(2017) John-Michael Gamble et al.   Lancet Diabetes & Endocrinology

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

(2017) Vanita R Aroda et al.   Lancet Diabetes & Endocrinology

Mortality in Type 1 Diabetes in the DCCT/EDIC Versus the General Population

(2016)   DIABETES CARE

Hypoglycemia and Cardiovascular Risk: Is There a Major Link?

(2016) Markolf Hanefeld et al.   DIABETES CARE

Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study)

(2016) V. R. Aroda et al.   DIABETES OBESITY & METABOLISM

Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register

(2016) Nils Ekström et al.   DIABETES OBESITY & METABOLISM

Exenatide improves β-cell function up to 3 years of treatment in patients with type 2 diabetes: a randomised controlled trial

(2016) Daniël H van Raalte et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials

(2016) Sylvie Erpeldinger et al.   BMC Endocrine Disorders

Systematic Reviews of Anesthesiologic Interventions Reported as Statistically Significant

(2015) Georgina Imberger et al.   ANESTHESIA AND ANALGESIA

Vildagliptin versus insulin in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea: results from a randomized, 24 week study

(2015) Thomas Forst et al.   CURRENT MEDICAL RESEARCH AND OPINION

Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial

(2015) An Tang et al.   DIABETES CARE

Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)

(2015) Francesco Giorgino et al.   DIABETES CARE

Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study

(2015) E. Araki et al.   DIABETES OBESITY & METABOLISM

Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy

(2015) Priscilla Hollander et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study

(2015) Mamta Jaiswal et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Comparative cardiovascular morbidity and mortality in patients taking different insulin regimens for type 2 diabetes: a systematic review

(2015) H. I. Price et al.   BMJ Open

Use of Antidiabetic Drugs in the U.S., 2003–2012

(2014) Christian Hampp et al.   DIABETES CARE

HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea

(2014) Peter N. Weissman et al.   DIABETOLOGIA

Association Between Intensification of Metformin Treatment With Insulin vs Sulfonylureas and Cardiovascular Events and All-Cause Mortality Among Patients With Diabetes

(2014) Christianne L. Roumie et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Bias in observational study designs: prospective cohort studies

(2014) P. Sedgwick   BMJ-British Medical Journal

Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial

(2014) Michaela Diamant et al.   Lancet Diabetes & Endocrinology

The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview

(2013) David M. Nathan et al.   DIABETES CARE

Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents

(2013) A. Philis-Tsimikas et al.   DIABETES OBESITY & METABOLISM

Efficacy and Safety Profile of Exenatide Once Weekly Compared With Insulin Once Daily in Japanese Patients With Type 2 Diabetes Treated With Oral Antidiabetes Drug(s): Results From a 26-Week, Randomized, Open-Label, Parallel-Group, Multicenter, Noninferiority Study

(2012) Nobuya Inagaki et al.   CLINICAL THERAPEUTICS

Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets

(2012) J. H. DeVries et al.   DIABETES CARE

Insulin degludec: overview of a novel ultra long-acting basal insulin

(2012) S. C. L. Gough et al.   DIABETES OBESITY & METABOLISM

Taspoglutide, a once-weekly glucagon-like peptide 1 analogue, vs. insulin glargine titrated to target in patients with Type 2 diabetes: an open-label randomized trial

(2012) M. Nauck et al.   DIABETIC MEDICINE

Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial

(2012) Pablo Aschner et al.   LANCET

The Past 200 Years in Diabetes

(2012) Kenneth S. Polonsky   NEW ENGLAND JOURNAL OF MEDICINE

Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia

(2012)   NEW ENGLAND JOURNAL OF MEDICINE

Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes

(2009) Mozhgan Dorkhan et al.   Cardiovascular Diabetology

Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study

(2009) M. J. Davies et al.   DIABETES OBESITY & METABOLISM

Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Intensive Glucose Lowering in Type 2 Diabetes

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes

(2008) William Duckworth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up

(2007) M. Alvarsson et al.   DIABETES OBESITY & METABOLISM